Best Pharmaceuticals for Children Act (BPCA)

BPCA authorizes research to improve the safety and efficacy of medication use for children. The goal of the act is to provide rigorous clinical data to improve drug label instructions. Please refer to the “About BPCA” page for more detailed information.

Since its authorization, the Best Pharmaceuticals for Children Act has assisted in updating 23 drug/device labels, enrolled more than 13,000 children in clinical trials, and completed 51 clinical trials.

BPCA activities include identifying off-patent drugs in need of further study, prioritizing pediatric therapeutics needs, and sponsoring clinical studies of prioritized drugs.
More >>
BPCA initiatives have led to publications and resources such as the BPCA Framework to Enable Pediatric Drug Development.
More >>
BPCA lecture series address key issues surrounding pediatric and maternal health.
More >>
The original BPCA was enacted in 2002 but has been reauthorized several times to continue improving the research and drug development process in pediatrics.
More >>